Subsquamous Intestinal Metaplasia: Implications for Endoscopic Management of Barrett's Esophagus

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 3, 2012, Pages 220-224

  Yachimski, Patrick ^a   Falk, Gary W ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; Esophageal Mucosa; Neoplasm; PPI; Risk; Treatment

Indexed keywords

PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CANCER RISK; CANCER SURGERY; ENDOSCOPIC SURGERY; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; REVIEW; STOMACH ACID; SUBSQUAMOUS INTESTINE METAPLASIA; TREATMENT OUTCOME; TUMOR BIOPSY;

BARRETT ESOPHAGUS; BIOPSY; EPITHELIUM; ESOPHAGEAL NEOPLASMS; HUMANS; METAPLASIA;

EID: 84857194090     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.10.009     Document Type: Review

References (33)

1. Falk G.W. Barrett's esophagus. Gastroenterology 2002, 122:1569-1591.
2. Liu W., Hahn H., Odze R.D., et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009, 104:816-824.
3. Kelty C.J., Gough M.D., Van Wyk Q., et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007, 42:1271-1274.
4. Sampliner R.E. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994, 89:1844-1848.
5. Cooper B.T., Chapman W., Neumann C.S., et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006, 23:726-733.
6. Sharma P., Morales T.G., Bhattacharyya A., et al. Squamous islands in Barrett's esophagus: what lies underneath?. Am J Gastroenterol 1998, 93:332-335.
7. Shaheen N.J., Sharma P., Overholt B.F., et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009, 360:2277-2288.
8. Bronner M.P., Overholt B.F., Taylor S.L., et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology 2009, 136:56-64.
9. Hornick J.L., Blount P.L., Sanchez C.A., et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. Am J Surg Pathol 2005, 29:372-380.
10. Biddlestone L.R., Barham C.P., Wilkinson S.P., et al. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998, 22:239-245.
11. Chennat J., Ross A.S., Konda V.J., et al. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management. Gastrointest Endosc 2009, 70:417-421.
12. Mino-Kenudson M., Ban S., Ohana M., et al. Buried dysplasia and early adenocarcinoma arising in Barrett esophagus after porfimer-photodynamic therapy. Am J Surg Pathol 2007, 31:403-409.
13. Overholt B.F., Panjehpour M., Halberg D.L. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003, 58:183-188.
14. Van Laethem J.L., Peny M.O., Salmon I., et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000, 46:574-577.
15. Odze R.D., Lauwers G.Y. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy 2008, 40:1008-1015.
16. Hornick J.L., Mino-Kenudson M., Lauwers G.Y., et al. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol 2008, 103:38-47.
17. Lewis C.J., Thrumurthy S.G., Pritchard S., et al. Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies. Surg Endosc 2011, 25:2564-2569.
18. Gray N.A., Odze R.D., Spechler S.J. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol 2011, 106:1899-1908.
19. Van Laethem J.L., Cremer M., Peny M.O., et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid-term results. Gut 1998, 43:747-751.
20. Sampliner R.E., Fennerty B., Garewal H.S. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. Gastrointest Endosc 1996, 44:532-535.
21. Shaheen N.J., Greenwald B.D., Peery A.F., et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010, 71:680-685.
22. Shaheen N.J., Overholt B.F., Sampliner R.E., et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011, 141:460-468.
23. Fleischer D.E., Overholt B.F., Sharma V.K., et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010, 42:781-789.
24. Phoa K.Y.N., Pouw R.E., Van Vilsteren F.G., et al. Radiofrequency ablation +/- endoscopic resection for Barrett's esophagus with high-grade dysplasia and/or early cancer: durability of the post-treatment neosquamous epithelium at 5-year follow-up. Gastrointest Endosc 2011, 73:AB198.
25. Pouw R.E., Gondrie J.J., Rygiel A.M., et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol 2009, 104:1366-1373.
26. Shaheen N.J., Peery A.F., Overholt B.F., et al. Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. Gastrointest Endosc 2010, 72:490-496.
27. Overholt B.F., Dean P.J., Galanko J.A., et al. Does ablative therapy for Barrett esophagus affect the depth of subsequent esophageal biopsy as compared with controls?. J Clin Gastroenterol 2010, 44:676-681.
28. Vakoc B.J., Shishko M., Yun S.H., et al. Comprehensive esophageal microscopy by using optical frequency-domain imaging (with video). Gastrointest Endosc 2007, 65:898-905.
29. Suter M.J., Vakoc B.J., Yachimski P.S., et al. Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. Gastrointest Endosc 2008, 68:745-753.
30. Adler D.C., Zhou C., Tsai T.H., et al. Three-dimensional optical coherence tomography of Barrett's esophagus and buried glands beneath neosquamous epithelium following radiofrequency ablation. Endoscopy 2009, 41:773-776.
31. Spechler S.J., Sharma P., et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091. American Gastroenterological Association.
32. Inadomi J.M., Somsouk M., Madanick R.D., et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009, 136:2101-2114.
33. Wani S., Falk G., Hall M., et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011, 9:220-227.